| Literature DB >> 36193313 |
Xia Han1, Danqing Li1, Shaofeng Zhang1.
Abstract
To address the issue of genetic mutations in medical records, clinical studies on minimally invasive surgery for breast cancer have been proposed. The CYP1B1 gene is mainly a single-nucleotide mutation, which affects the enzymatic reaction related to carcinogens and causes the susceptibility differences of different individuals. First, the survival rate and other factors influencing the estimation of 120 leukemia patients were examined with the help of various medical records by establishing an organization for auxiliary diagnosis of lung cancer based on expertise. Secondly, through the treatment of 120 leukemia patients after minor surgery, the average life expectancy of 120 patients was 19 months, the one-year survival rate was 74.61%, and the two-year survival rate was 32.70%. Currently, there are more than 160 cases of CYP1B1 discovered. In recent years, people have gradually entered into in-depth research on the correlation between genes and lung cancer, which is of great significance to the treatment and research of lung cancer. An analysis showed patients' age, stage, whether they would work, whether radiation therapy and antibiotics were offered, and so on. s has a direct impact on patient survival, and many tests have shown that the patient's age, stage, whether it will work, and whether fire radiation and drug therapy are provided are important interventions for patients with anemia. Finally, in patients with leukemia, especially during the restricted period, combined treatment with a physician, radiologist, and surgeon should be initiated as soon as possible. For a wide range of disease, depending on the use of chemotherapy, local metastasis with antibiotics can improve the disease. After success, it is more beneficial to choose second-line treatment.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36193313 PMCID: PMC9526583 DOI: 10.1155/2022/5217625
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.246
Figure 1CYP1B1 gene polymorphism and minimally invasive surgery in lung cancer.
Inspection items.
| Reference range | Inspection name | State | Result value | |
|---|---|---|---|---|
| Blood routine examination | 0-0.1 | Basophil | Normal | 0.01 |
| 0.04-0.6 | Eosinophils | Normal | 0.13 | |
| 0-2 | Basophil ratio | Normal | 0.3% | |
| 120-170 | Hemoglobin | Normal | 125 g/L | |
| 100-400 | Platelet | Normal | 168 g/L | |
| 4.5-6.5 | Red blood cell | Normal | 5.25 | |
| 27-60 | Red blood cell distribution width | Normal | 51.6% | |
| 5-10 | White blood cell | Normal | 7.23 g/L | |
| 75-100 | Red blood cell volume | Normal | 92.46 L |
Figure 2Proportion of patients.
Figure 3Different onset time.
Clinicopathological features of various lesions.
| Clinicopathological features | Cases (%) | |
|---|---|---|
| Total number of lesions | 286 | |
| Lesion distribution | Upper lobe of the right lung | 78 (34.26%) |
| Middle lobe of the right lung | 32 (11.23%) | |
| Lower lobe of the right lung | 53 (24.21%) | |
| Upper lobe of the left lung | 41 (15.39%) | |
| Lower lobe of the left lung | 52 (16.87%) | |
| Maximum diameter of the tumor | ≤4 cm | 314 (68.67%) |
| Lymph node metastasis | ≥4 cm | 17 (5.43%) |
| Yes | 14 (7.71%) | |
| No | 254 (95.21%) | |
| Differentiation type | High differentiation | 6 (3.29%) |
| High to medium differentiation | 14 (5.01%) | |
| Medium differentiation | 76 (31.43%) | |
| Medium to low differentiation | 18 (7.74%) | |
| Low differentiation | 3 (1.13%) | |
| Not reported | 134 (34.76%) | |
| Pleural invasion | Yes | 14 (7.23%) |
| No | 235 (99.34%) |
Gene mutation in patients with multiple primary lung cancer.
| Case | Lesion A mutation type | Focus B mutation type | Lesion A and B detection method | Pathological type of lesions A and B |
|---|---|---|---|---|
| 1 | EDFR17 | EGFR17 | All of them are NGS9 genes | Glandular scale |
| 2 | Kras | ERBB3 | All of them are NGS124 genes | Gland |
| 3 | ROSI TP43 | KRAS | NGS520-NGS7 gene | Gland |
| 4 | FGFR 23 | TP-56 | NGSI4 gene-NGS45 gene | Glandular—poorly differentiated |
Univariate analysis of the relationship between clinicopathological features and DFS.
| Clinicopathological features | Number of cases | Average DFS |
|
|
|---|---|---|---|---|
| Gender | 3.321 | 0.087 | ||
| Male | 42 | 35.549 (35.146-41.245) | ||
| Female | 78 | 56.543 (42.678-53.517) | ||
| Age (years) | 1.129 | 0.213 | ||
| <60 | 68 | 56.187 (41.982-52.673) | ||
| ≥60 | 53 | 44.156 (40.189-51.649) | ||
| Smoking history | 5.471 | 0.041 | ||
| Yes | 30 | 33.875 (32.216-44.209) | ||
| No | 87 | 54.127 (51.549-58.298) | ||
| Number of lesions | 0.043 | 0.769 | ||
| 3 | 122 | 49.127 (43.540-56.734) | ||
| ≥5 | 15 | 38.763 (31.843-41.731) | ||
| Maximum diameter of the tumor | 8.328 | 0.06 | ||
| ≤4 cm | 79 | 51.426 (46.183-56.197) | ||
| ≥4 cm | 41 | 44.129 (38.671-52.851) |
Clinicopathological features of various lesions.
| Clinicopathological features | Number of cases (%) | |
|---|---|---|
| TNM staging | Neuroendocrine carcinoma | 3 (0.68%) |
| Atypical carcinoid | 2 (0.43%) | |
| Poorly differentiated carcinoma | 2 (0.37%) | |
| Tis | 38 (19.34%) | |
| LA | ||
| LA1 | 114 (43.48%) | |
| LA2 | 47 (24.46%) | |
| LA3 | 16 (6.23%) |
Figure 4Relationship curve between independent risk factors and DFS.
Figure 5Relationship curve between the sum of the maximum tumor diameter and DFS.
Figure 6Relationship curve between the pathological type and DFS.